Title

Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam

Document Type

Article

Publication Date

10-2016

Keywords

fsc2017

Abstract

In lieu of an abstract, here is the article's first paragraph:

"A global crisis of antibiotic resistance is ongoing, especially with resistant gram-negative pathogens including Pseudomonas spp, carbapenemase-producing Enterobacteriaceae, and extended-spectrum β-lactamase (ESBL)-producing organisms. The increasing rate of methicillin-resistant Staphylococcus aureus (MRSA) infections is also a concern.1 One newer intravenous cephalosporin (ceftaroline) was approved in 2010, and 2 new intravenous cephalosporin–β-lactamase inhibitor combinations (ceftolozane-tazobactam and ceftazidime-avibactam) have recently been approved to try to combat these resistant organisms in adult patients."

DOI

10.4037/aacnacc2016612